Equillium, Inc. — fact timeline

Equillium, Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. valued at approximately $35.0 million (effective 2026-03-11).

“On March 11, 2026, Equillium, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Healthcare Fund, L.P. (the “Investor”), pursuant to which the Company agreed to sell and issue shares (“Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and a pre-funded warrant to purchase shares of Common Stock (“Warrant Shares”), in a private placement transaction (the “Private Placement”).”

Equillium, Inc. engaged Crowe LLP as its auditor.

“On October 21, 2025, Crowe confirmed that such client acceptance procedures were complete, and the Company and Crowe executed an engagement letter to engage Crowe as the Company's independent registered public accounting firm.”

Equillium, Inc. engaged Crowe LLP as its auditor.

“On September 30, 2025, the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to the execution of an engagement letter and completion of Crowe’s standard client acceptance procedures.”

Equillium, Inc. dismissed KPMG LLP as its auditor.

“On September 30, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Equillium, Inc. (the “Company”) approved dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on September 30, 2025.”

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 13, 2024, Equillium, Inc. (the “ Company ” ) received a notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the minimum bid price of the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days (the “ Minimum Bid Price Requirement ”). The Company was given 180 days, or until June 11, 2025, to regain compliance with the Minimum Bid Price Requirement. On June 12, 2025, the Company received a notice from Nasdaq that the Company was granted an additional 180 calen”

Equillium, Inc. reported the first quarter ended March 31, 2024 results: revenue $10.7 million, net income $2.7 million, EPS $(0.08) per basic and diluted share.

“1 Option exercise payment is denominated in Japanese yen (5 billion) and subject to currency exchange rates at the time of payment. Revenue for the first quarter of 2024 was $10.7 million, compared to $8.9 million during the same period in 2023. Revenue in the first quarters of 2024 and 2023 consisted entirely of itolizumab development funding and amortization of”